Which Stock Will Rally: Halozyme Therapeutics or Incyte?
Even as Incyte surged 12% during the past Week, its peer Halozyme Therapeutics may be a better choice. Consistently evaluating alternatives is core to sound investment approach. Halozyme Therapeutics (HALO) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Incyte (INCY) stock, suggesting you may be better off investing in HALO
- HALO’s quarterly revenue growth was 22.1%, vs. INCY’s 20.0%.
- In addition, its Last 12 Months revenue growth came in at 31.2%, ahead of INCY’s 18.1%.
- HALO leads on profitability over both periods – LTM margin of 59.3% and 3-year average of 49.8%.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. Trefis works with Empirical Asset Management — a Boston area wealth manager — whose asset allocation strategies yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Empirical has incorporated the Trefis HQ Portfolio in this asset allocation framework to provide clients with higher returns while taking on lower levels of risk versus the benchmark index.
INCY develops proprietary therapeutics, including ruxolitinib for chronic GVHD and Retifanlimab in Phase II trials for various cancers. Incorporated in 1991, headquartered in Wilmington, Delaware. HALO biopharma platform developing ENHANZE drug delivery technology and therapies like Perjeta, RITUXAN HYCELA, and MabThera SC for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Valuation & Performance Overview
| INCY | HALO | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 16.0 | 10.8 | HALO |
| Revenue Growth | |||
| Last Quarter | 20.0% | 22.1% | HALO |
| Last 12 Months | 18.1% | 31.2% | HALO |
| Last 3 Year Average | 13.1% | 29.0% | HALO |
| Operating Margins | |||
| Last 12 Months | 26.1% | 59.3% | HALO |
| Last 3 Year Average | 13.8% | 49.8% | HALO |
| Momentum | |||
| Last 3 Year Return | 33.1% | 46.1% | HALO |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: INCY Revenue Comparison | HALO Revenue Comparison
See more margin details: INCY Operating Income Comparison | HALO Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell HALO Stock to see if Halozyme Therapeutics’s edge holds up under the hood or if Incyte still has cards to play (see Buy or Sell INCY Stock).
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| INCY Return | -0% | -16% | 9% | -22% | 10% | 49% | 7% | ||
| HALO Return | 141% | -6% | 42% | -35% | 29% | 42% | 268% | <=== | |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 15% | 112% | ||
| Monthly Win Rates [3] | |||||||||
| INCY Win Rate | 42% | 50% | 67% | 58% | 58% | 80% | 59% | ||
| HALO Win Rate | 83% | 42% | 58% | 33% | 50% | 60% | 54% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | 64% | <=== | |
| Max Drawdowns [4] | |||||||||
| INCY Max Drawdown | -28% | -27% | -10% | -35% | -18% | -20% | -23% | ||
| HALO Max Drawdown | -22% | -25% | -20% | -47% | -9% | -0% | -21% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 11/4/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read HALO Dip Buyer Analyses and INCY Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.
Whatever your view on either of these stocks, investing in one or two stocks remains a risky proposition. Instead, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.